Invitrogen SuperScript III Reverse Transcriptase is a genetically engineered MMLV reverse transcriptase (RT) created by the introduction of several mutations for reduced RNase H activity, increased half-life, and improved thermal stability. SuperScript III RT offers higher cDNA yields, improved cDNA lengths, improved efficiency on GC-rich target RNAs, and overall better performance than wild-type MMLV and MMLV RNase H-minus enzymes.

SuperScript RTs are the most highly trusted and widely used RTs with over 50,000 citations, reviews, and publications to date. The enzyme is purified to near homogeneity from E. coli containing the modified pol gene of Moloney Murine Leukemia Virus.

Features of SuperScript III Reverse Transcriptase include:
• First-strand cDNA may be synthesized at temperatures up to 55°C
• cDNA can be generated from 100 bp to >12 kb
• Increased specificity
• High yields of cDNA and full-length products

Note: The latest member of the SuperScript RT family, SuperScript IV Reverse Transcriptase, features enhanced thermostability, processivity, yields, and performance with any RNA samples, including those of suboptimal purity or integrity.